Company intelligence / Profile preview

ImevaX

Munich, Bavaria, Germanyimevax.com ↗

Ownership: Private
Development stage: Phase 1

Overview

ImevaX has developed a pipeline focused on combating chronic and hospital-acquired infections through specific vaccines and diagnostics. Its lead vaccine candidate IMX101 targets H. pylori by neutralizing its immune evasion mechanism, with preclinical/early clinical progress reported. The company also markets Pylori DuoTect®, a rapid point-of-care test for H. pylori antibodies that delivers results within 20 minutes.

Therapeutic areas: Infectious Diseases
Modalities: Vaccinesin vitro diagnostics (rapid antibody tests)
Industry: Biotech

Drug pipeline

2 assets

IMX101

1 more asset in the full pipeline.

Request access →

Partnerships

Institute of Microbiology at Technical University Munich (TUM)

Beyond the preview

Go deeper on ImevaX.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ImevaX.

Explore the full profile